FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199105087> ?p ?o ?g. }

• W3199105087 endingPage "121" @default.
• W3199105087 startingPage "119" @default.
• W3199105087 abstract "Future Medicinal ChemistryVol. 14, No. 3 EditorialChallenges and opportunities for in vivo PROTAC deliveryAndrew B Benowitz, Paul T Scott-Stevens & John D HarlingAndrew B Benowitz *Author for correspondence: E-mail Address: andrew.b.benowitz@GSK.comhttps://orcid.org/0000-0002-9913-605XMedicine Design, GlaxoSmithKline, Gunnels Wood Road, Stevenage, SG1 2NY, UKSearch for more papers by this author, Paul T Scott-StevensIn Vitro/In Vivo Translation, GlaxoSmithKline, Gunnels Wood Road, Stevenage, SG1 2NY, UKSearch for more papers by this author & John D HarlingMedicine Design, GlaxoSmithKline, Gunnels Wood Road, Stevenage, SG1 2NY, UKSearch for more papers by this authorPublished Online:16 Sep 2021https://doi.org/10.4155/fmc-2021-0223AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: chameleonicityoral exposureparenteral deliveryPROTACReferences1. Nalawansha DA, Crews CM. PROTACs: an emerging therapeutic modality in precision medicine. Cell Chem. Biol. 27(8), 998–1014 (2020).Crossref, Medline, CAS, Google Scholar2. Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45(12), 2615–2623 (2002).Crossref, Medline, CAS, Google Scholar3. Lee GT, Nagaya N, Desantis J et al. Effects of MTX-23, a novel PROTAC of androgen receptor splice variant-7 and androgen receptor, on CRPC resistant to second-line antiandrogen therapy. Mol. Cancer Ther. 20(3), 490–499 (2021).Crossref, Medline, CAS, Google Scholar4. Luo G, Li Z, Lin X et al. Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo. Acta Pharm. Sin. B 11(5), 1300–1314 (2021).Crossref, Medline, CAS, Google Scholar5. Whitty A, Zhong M, Viarengo L, Beglov D, Hall DR, Vajda S. Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs. Drug Discov. Today 21(5), 712–717 (2016).Crossref, Medline, CAS, Google Scholar6. Atilaw Y, Poongavanam V, Svensson Nilsson C et al. Solution conformations shed light on PROTAC cell permeability. ACS Med. Chem. Lett. 12(1), 107–114 (2021).Crossref, Medline, CAS, Google Scholar7. David L, Wenlock M, Barton P, Ritzén A. Prediction of chameleonic efficiency. ChemMedChem 16(17), 2669–2685 (2021).Crossref, Medline, CAS, Google Scholar8. Ermondi G, Garcia Jimenez D, Rossi Sebastiano M, Caron G. Rational control of molecular properties is mandatory to exploit the potential of PROTACs as oral drugs. ACS Med. Chem. Lett. 12(7), 1056–1060 (2021).Crossref, Medline, CAS, Google Scholar9. Hodge D, Back DJ, Gibbons S, Khoo SH, Marzolini C. Pharmacokinetics and drug–drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin. Pharmacokinet. 60(7), 835–853 (2021).Crossref, Medline, CAS, Google Scholar10. Miah AH, Smith IED, Rackham M et al. Optimization of a series of RIP2 PROTACs. J. Med. Chem. 64(17), 12978–13003 (2021).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited BySpecial Focus Issue – Targeted protein degradation: a new paradigm in medicinal chemistryHarriet Wall26 January 2022 | Future Medicinal Chemistry, Vol. 14, No. 3 Vol. 14, No. 3 Follow us on social media for the latest updates Metrics Downloaded 913 times History Received 2 August 2021 Accepted 1 September 2021 Published online 16 September 2021 Published in print February 2022 Information© 2021 Newlands PressKeywordschameleonicityoral exposureparenteral deliveryPROTACFinancial & competing interests disclosureThe authors are employees and/or shareholders of GlaxoSmithKline. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W3199105087 created "2021-09-27" @default.
• W3199105087 creator A5002258281 @default.
• W3199105087 creator A5048107174 @default.
• W3199105087 creator A5090314845 @default.
• W3199105087 date "2022-01-01" @default.
• W3199105087 modified "2023-10-10" @default.
• W3199105087 title "Challenges and opportunities for <i>in vivo</i> PROTAC delivery" @default.
• W3199105087 cites W2105649494 @default.
• W3199105087 cites W2279263454 @default.
• W3199105087 cites W3049656208 @default.
• W3199105087 cites W3095673375 @default.
• W3199105087 cites W3108430752 @default.
• W3199105087 cites W3117557114 @default.
• W3199105087 cites W3145353426 @default.
• W3199105087 cites W3166162063 @default.
• W3199105087 cites W3167295725 @default.
• W3199105087 cites W3193606728 @default.
• W3199105087 doi "https://doi.org/10.4155/fmc-2021-0223" @default.
• W3199105087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34528453" @default.
• W3199105087 hasPublicationYear "2022" @default.
• W3199105087 type Work @default.
• W3199105087 sameAs 3199105087 @default.
• W3199105087 citedByCount "10" @default.
• W3199105087 countsByYear W31991050872022 @default.
• W3199105087 countsByYear W31991050872023 @default.
• W3199105087 crossrefType "journal-article" @default.
• W3199105087 hasAuthorship W3199105087A5002258281 @default.
• W3199105087 hasAuthorship W3199105087A5048107174 @default.
• W3199105087 hasAuthorship W3199105087A5090314845 @default.
• W3199105087 hasConcept C121608353 @default.
• W3199105087 hasConcept C126322002 @default.
• W3199105087 hasConcept C161191863 @default.
• W3199105087 hasConcept C207001950 @default.
• W3199105087 hasConcept C2780192828 @default.
• W3199105087 hasConcept C41008148 @default.
• W3199105087 hasConcept C54355233 @default.
• W3199105087 hasConcept C61367390 @default.
• W3199105087 hasConcept C71924100 @default.
• W3199105087 hasConcept C86803240 @default.
• W3199105087 hasConcept C98274493 @default.
• W3199105087 hasConceptScore W3199105087C121608353 @default.
• W3199105087 hasConceptScore W3199105087C126322002 @default.
• W3199105087 hasConceptScore W3199105087C161191863 @default.
• W3199105087 hasConceptScore W3199105087C207001950 @default.
• W3199105087 hasConceptScore W3199105087C2780192828 @default.
• W3199105087 hasConceptScore W3199105087C41008148 @default.
• W3199105087 hasConceptScore W3199105087C54355233 @default.
• W3199105087 hasConceptScore W3199105087C61367390 @default.
• W3199105087 hasConceptScore W3199105087C71924100 @default.
• W3199105087 hasConceptScore W3199105087C86803240 @default.
• W3199105087 hasConceptScore W3199105087C98274493 @default.
• W3199105087 hasIssue "3" @default.
• W3199105087 hasLocation W31991050871 @default.
• W3199105087 hasLocation W31991050872 @default.
• W3199105087 hasOpenAccess W3199105087 @default.
• W3199105087 hasPrimaryLocation W31991050871 @default.
• W3199105087 hasRelatedWork W1864918391 @default.
• W3199105087 hasRelatedWork W1984464970 @default.
• W3199105087 hasRelatedWork W2071753433 @default.
• W3199105087 hasRelatedWork W2131077462 @default.
• W3199105087 hasRelatedWork W2157355069 @default.
• W3199105087 hasRelatedWork W2611803138 @default.
• W3199105087 hasRelatedWork W2888003396 @default.
• W3199105087 hasRelatedWork W3111390827 @default.
• W3199105087 hasRelatedWork W4295900113 @default.
• W3199105087 hasRelatedWork W4387341186 @default.
• W3199105087 hasVolume "14" @default.
• W3199105087 isParatext "false" @default.
• W3199105087 isRetracted "false" @default.
• W3199105087 magId "3199105087" @default.
• W3199105087 workType "article" @default.